Skip to main content

CORRECTION article

Front. Immunol., 30 November 2022
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1099535

Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

This article is a correction to:

  1. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

    1. Read original article
Saeedeh Ghorbanalipoor&#x;Saeedeh Ghorbanalipoor1‡Shirin Emtenani&#x;Shirin Emtenani1‡Melissa ParkerMelissa Parker2Mayumi KamaguchiMayumi Kamaguchi1Colin OsterlohColin Osterloh1Manuela PigorsManuela Pigors1Natalie GrossNatalie Gross1Stanislav Khil&#x;chenkoStanislav Khil’chenko1Anika KasprickAnika Kasprick1Sabrina PatzeltSabrina Patzelt1Diana WortmannDiana Wortmann1Ibrahim O. IbrahimIbrahim O. Ibrahim1Kentaro IzumiKentaro Izumi1Stephanie GoletzStephanie Goletz1Katharina BochKatharina Boch3Kathrin KaliesKathrin Kalies4Katja BieberKatja Bieber1Paul Smith&#x;Paul Smith2†Enno Schmidt Enno Schmidt1§Ralf J. Ludwig* Ralf J. Ludwig1*§
  • 1Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany
  • 2Incyte Research Institute, Wilmington, DE, United States
  • 3Department of Dermatology, University of Lübeck, Lübeck, Germany
  • 4Institute of Anatomy, University of Lübeck, Lübeck, Germany

A Corrigendum on
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.

by Ghorbanalipoor S, Emtenani S,Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil’chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E and Ludwig RJ (2022) Front. Immunol. 13:865241. doi: 10.3389/fimmu.2022.865241

In the published article, there was an error in the author list. The equal contribution of Saeedeh Ghorbanalipoor, Shirin Emtenani as first authors and that of Enno Schmidt and Ralf J. Ludwig as last authors had not been indicated. The corrected author list appears below.

Saeedeh Ghorbanalipoor1‡, Shirin Emtenani1‡, Melissa Parker2, Mayumi Kamaguchi 1, Colin Osterloh 1, Manuela Pigors 1, Natalie Gross 1, Stanislav Khil’chenko 1, Anika Kasprick 1, Sabrina Patzelt1, Diana Wortmann1, Ibrahim O. Ibrahim1, Kentaro Izumi1, Stephanie Goletz1, Katharina Boch3, Kathrin Kalies4, Katja Bieber1, Paul Smith2†, Enno Schmidt1§ and Ralf J. Ludwig1*§

†Present Address: Paul Smith, Connect Biopharma, San Diego, CA, United States

‡These authors have contributed equally to this work

§These authors have contributed equally to this work

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: animal model, neutrophils, autoimmunity, pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid, signal transduction, phosphatidylinositol 3-kinase (P13k)

Citation: Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil’chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E and Ludwig RJ (2022) Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases. Front. Immunol. 13:1099535. doi: 10.3389/fimmu.2022.1099535

Received: 15 November 2022; Accepted: 16 November 2022;
Published: 30 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Ghorbanalipoor, Emtenani, Parker, Kamaguchi, Osterloh, Pigors, Gross, Khil’chenko, Kasprick, Patzelt, Wortmann, Ibrahim, Izumi, Goletz, Boch, Kalies, Bieber, Smith, Schmidt and Ludwig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ralf J. Ludwig, cmFsZi5sdWR3aWdAdWtzaC5kZQ==

†Present address: Paul Smith, Connect Biopharma, San Diego, CA, United States

‡These authors have contributed equally to this work

§These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.